Trade Summary

1 week ago, Urist Marshall, serving as EVP, Research, Investments at Royalty Pharma Plc (RPRX), sold 20,000 shares at $38.38 per share, for a total transaction value of $767,582.00. Following this transaction, Urist Marshall now holds 146,418 shares of RPRX.

This sale represents a 12.00% decrease in Urist Marshall's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, December 19, 2025 and publicly disclosed via SEC Form 4 filing on Monday, December 22, 2025, 3 days after the trade was made.

Royalty Pharma Plc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.